Nitin Gadkari dials Sun Pharma chief to cope with Remdesivir shortage in Nagpur

Published On 2021-04-12 08:07 GMT   |   Update On 2021-04-12 12:53 GMT

Nagpur: Union minister Nitin Gadkari has called up Sun Pharma's chief to arrange for 10,000 injections of Remdesivir in Nagpur in view of a shortage of the medicine here in Maharashtra. Remdesivir is considered a key anti-viral drug in the fight against COVID-19, especially in adult patients with severe complications.A press release from Gadkari's office on Saturday said the Lok Sabha member...

Login or Register to read the full article

Nagpur: Union minister Nitin Gadkari has called up Sun Pharma's chief to arrange for 10,000 injections of Remdesivir in Nagpur in view of a shortage of the medicine here in Maharashtra. Remdesivir is considered a key anti-viral drug in the fight against COVID-19, especially in adult patients with severe complications.

A press release from Gadkari's office on Saturday said the Lok Sabha member from Nagpur spoke to Sun Pharma's Managing Director Dilip Shanghvi over phone to inform him about the situation here and appealed to him to make available the Remdesivir injections.
The pharma company chief assured Gadkari of making available 5,000 injections immediately on Saturday and the remaining 5,000 in next two-three days, the release said.
Gadkari also appealed to the people of Nagpur to follow all COVID-19 prevention protocols.
With Maharashtra witnessing a spurt in COVID-19 cases, Remdesivir injections are in high demand in the state.
Maharashtra Revenue Minister Balasaheb Thorat on Saturday said there is shortage of Remdesivir injections and the supply of vaccine doses was inadequate.
On Thursday, the state government capped the price of Remdesivir between Rs 1,100 and Rs 1,400 per vial and warned against its hoarding and black marketing.


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News